Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Barbara D. Cruz*, Mariana M. Barbosa, Lucas L. Torres, Pamela S. Azevedo, Vânia E.A. Silva, Brian Godman, Juliana Alvares-Teodoro

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences